A prospective animal study.
It has been suggested that pulmonary arterial pressures in persistent pulmonary hypertension of the newborn could be selectively reduced by intravenous (i.v.) magnesium sulfate (MgSO 4 ) therapy. 1 In an uncontrolled study on human neonates, Abu-Osba et al. 2 treated nine infants with persistent pulmonary hypertension secondary to meconium aspiration syndrome, congenital diaphragmatic hernia, and sepsis with infusions of MgSO 4 . Pulmonary artery pressure (PAP) was not measured; however, they suggested that the observed increase in PAO 2 , reported in eight of the nine infants, was probably related to the vasodilator effects of MgSO 4 on the pulmonary vessels. Our own clinical experience with MgSO 4 infusions in critically ill newborns suggests that it was unlikely to be a selective pulmonary vasodilator and that systemic blood pressure decreases with MgSO 4 infusions. This observation is supported by a study published in abstract form by Abu-Osba et al. 3 on the effects of MgSO 4 on a hypoxia-induced model of pulmonary hypertension in adult sheep. I.v. infusions of MgSO 4 (100 mg/ kg) were associated with a decrease in PAP of 34.6% ( p Ͻ 0.05) and a decrease in mean arterial pressure of 37.4%. These data suggest that there was no change in the ratio of pulmonary vascular resistance index (PVRI) to systemic vascular resistance index (SVRI) after MgSO 4 .
In a previous study of the effects of MgSO 4 in a neonatal model of hypoxia-induced pulmonary hypertension, we demonstrated that MgSO 4 did not have a differential effect on the systemic and pulmonary circulations. 4 However, different models of persistent pulmonary hypertension of the newborn may have different responses to therapeutic agents. The current study was performed to determine any Original Article
potentially beneficial therapeutic effects of MgSO 4 in a neonatal animal model of meconium aspiration syndrome.
METHODS
Eight mixed strain newborn piglets were obtained on day 1 or 2 of life. The surgical technique and experimental protocol were approved by the Animal Care Committee of the University of Alberta.
Surgical Technique
General anesthesia was induced with 5% halothane and maintained with oxygen (5 1/minute) and 2% halothane. An incision in the right side of the neck was made, and a catheter was inserted through the external jugular vein and advanced to the right atrium to measure right atrial pressure. A catheter was inserted into the right carotid artery to continuously measure mean systemic arterial pressure (SAP). Halothane was discontinued and 20 g/kg fentanyl and 0.2 mg/kg acepromazine, followed by a continuous infusion of fentanyl (10 g/kg per hour), were given i.v. A 3.0-mm endotracheal tube was inserted through a tracheostomy. Muscle relaxation was maintained by i.v. pancuronium bromide (100 g/kg) every 45 minutes. Ventilation of the animal was initiated with a peak inspiratory pressure of 12 to 14 cm H 2 O, a positive end expiratory pressure of 2 cm H 2 O, a rate of 35 to 40 breaths per minute, and an inspiratory time of 0.35 second (Sechrist IV 100B; Sechrist Industries, Anaheim, CA). The FIO 2 was adjusted to maintain arterial oxygen saturation (SAO 2 ) at Ͼ95%. Arterial blood gas values were maintained at a pH of 7.35 to 7.45, a PCO 2 of 35 to 45 mm Hg, and a PO 2 of 60 to 80 mm Hg (IL Micro 13 pH/Blood Gas Analyzer; Instrumentation Laboratories, Fisher Scientific, Lexington, MA) by appropriate ventilator adjustments. The SAO 2 was measured using a transcutaneous pulse oximeter (N200; Nellcor, Hayward, CA). Hydration during surgery was maintained with 30 ml/kg per hour of sodium bicarbonate (15 meq/100 ml) in 5% dextrose to compensate for high insensible losses through the thoracotomy, and to prevent severe acidosis during periods of hypoxia.
A 6-or 8-mm Transonic transit time ultrasound flow probe (Transonics Corporation, Ithaca, NY) inserted through a left thoracotomy was placed around the main pulmonary artery to measure cardiac output. A similar flow probe was placed around the ductus arteriosus. A 22-gm catheter was inserted into the root of the pulmonary artery through a purse string suture to measure the PAP. Confirmation of catheter placement was made by identifying the characteristic wave forms. Arterial, atrial, and pulmonary artery catheters were connected to a pressure transducer (model 1290A; Hewlett Packard, Palo Alto, CA) and zeroed at the midcardiac level; signals were recorded and displayed with a monitor (model 78833B; Hewlett Packard, Waltham, MA). Body temperature was monitored continuously with a rectal probe connected to a Hewlett Packard monitor and maintained between 38 and 39°C using a heating pad.
Data Collection
Data were collected continuously in a 486 personal computer (Dell, Richmond Hill, Ontario, Canada) using an analog to a digital converter (DT2801; Data Translation Inc., Marlborough, MA) and the Asyst scientific software system (Macmillan Software, Macmillan USA, Indianapolis, IN). All signals were acquired at 24 Hz, and programs were written to create correctly configured files and to acquire, store, and analyze the data. The PVRI (mm Hg/(ml/kg per minute)) was calculated as the quotient of PAP and the cardiac index (Q); SVRI (mm Hg/(ml/kg/min)) was calculated as the quotient of SAP minus right atrial pressure and Q.
Medications and Preparations
Magnesium sulfate heptahydrate (MgSO 4 7H 2 O; Abbott Laboratories, Abbott Park, IL) (50% solution) was diluted to the equivalent of MgSO 4 25 mg/kg (equivalent to 0.1 mM/kg magnesium) per 2 ml of normal saline. Human meconium was obtained from infants of Ͻ18 hours of age and kept in an airtight container to prevent desiccation. A 20% solution in normal saline was mixed manually.
Experimental Design
Baseline recordings were taken for 10 minutes after the animal had become stable after the instrumentation; animals were ventilated with 90% oxygen. Meconium was then instilled down the endotracheal tube in a dose of 2 ml/kg and manually ventilated deep into the animal's lungs; the animal was then reattached to the infant ventilator. This procedure led to acute oxygen desaturation of the animal, with gradual recovery over 2 to 3 minutes to a lower saturation than the previous baseline. The process was then repeated at 5-minute intervals with 1-ml/kg aliquots of 20% fresh human meconium until the baseline recovery saturation was Ͻ75% by pulse oximeter. At this time, a baseline blood gas was taken and a recording was made for ϳ5 minutes.
At this time, three animals were monitored for 40 minutes without further intervention and subsequently sacrificed. The remaining five animals were given magnesium sulfate as detailed below.
Magnesium sulfate heptahydrate was administered i.v. in doses of 25 mg/kg on four occasions for a total dose of 100 mg/kg. Recordings were made continuously during this time. After the pressures had stabilized, with less than a 5% change in 1 minute, and at least 5 minutes after the administration of MgSO 4 , a 2-minute section of the record was marked for averaging. The results used for statistical analysis and shown in the figures and in Table 1 are the average values from this section of the recording. A blood gas was taken at this time and the next dose of MgSO 4 was then given. After the final aliquot of MgSO 4 was administered, an additional 10 minutes of recording was performed.
Statistical Analysis
Repeated measures analysis of variance was used with a significance level of 0.05. Fisher's least significant difference was used as the posthoc test to determine which time periods showed a significant difference from the baseline, but only in the case of a significant overall analysis of variance. The results are presented as mean and SD.
RESULTS
All eight piglets, aged 1 to 2 days and weighing 1.1 to 1.7 kg (mean 1.4, SD 0.2 kg) survived to complete the experiment. Baseline saturation averaged 100% (SD 2), mean PACO 2 was 35 torr (SD 4) (4.7 SD, 0.5 kPa), and mean pH was 7.38 (SD 0.22); baseline values of hemodynamic variables are given in Table 1 . The meconium instillation procedure led to marked systemic desaturation followed by a slow progressive recovery. After the animals stabilized, the mean SAO 2 was 73.4% (SD 10), mean PACO 2 was 94 torr (SD 8) (12.5 SD, 1.1 kPa), and arterial pH was 7.08 (SD 0.04). The PAP increased from 24 mm Hg (SD 5) (3.2 SD, 0.6 kPa) to 52 mm Hg (SD 5) (6.9 SD, 0.7 kPa), the systemic pressure decreased from 88 mm Hg (SD 17) to 78 mm Hg (SD 15) (from 11.8 SD and 2.2 kPa to 10.3 SD and 2.3 kPa). The effects of meconium instillation on cardiac index, SVRI, PVRI, and PVRI/SVRI ratio are noted in Table 1 .
The control animals had no significant change in any of the measured variables for the 40 minutes of the recording period ( Table 1) .
The administration of MgSO 4 was associated with transient bradycardia, systemic and pulmonary hypotension, and a fall in cardiac index, with partial recovery toward baseline in the 5 minutes after administration. The nadir of the cardiac index occurred at 30 seconds after the administration of the MgSO 4 , at which time the cardiac index had fallen by 24% from the previous level ( p Ͻ 0.05). Complete recovery to preMgSO 4 levels was not observed in any animal. Figure 1 shows a segment from the record of one of the animals demonstrating the transient effects of MgSO 4 on heart rate, SAO 2 , and SAP after the first dose (25 mg/kg).
The effects of MgSO 4 on SAO 2 , measured after the period of stabilization, are shown in Figure 2 ; results were obtained between 5 and 7 minutes after finishing the MgSO 4 bolus. There was a significant decrease in SAO 2 after the third and fourth doses of MgSO 4 (cumulative doses of 75 and 100 mg/kg, respectively, p Ͻ 0.05). MgSO 4 (75 and 100 mg/kg cumulative dose) was associated with significant reductions in PAP and mean SAP (Figure 3 , both p Ͻ 0.05) as well as in SVRI and PVRI, both p Ͻ 0.05, whereas the cardiac index and PVRI/SVRI ratio remained unchanged (Table 1) . Ductal flow was not detected at any time during the study.
DISCUSSION
For an agent to improve oxygenation in the complex condition of persistent pulmonary hypertension of the newborn, there must be a selective reduction in PVRI over SVRI and/or an improvement in ventilation perfusion mismatch. In this animal model, which does not have right-to-left shunting (as indeed is the case for all animal models of pulmonary hypertension of the newborn so far described), changes in oxygenation must largely be dependent on ventilation perfusion matching. In the present study, ductal flow was not detected and the PVRI/SVRI ratio remained unchanged after MgSO 4 , indicating that there was no differential alteration in systemic versus pulmo- 99 (1) 76 (11) 82 (9) RAP ϭ right atrial pressure. *p Ͻ 0.05 compared with post-meconium values by one-way repeated measures analysis of variance, followed by Fisher's least significant difference.
nary vascular resistance. Thus, we have demonstrated that MgSO 4 does not have a selective effect in reducing PAPs in this piglet model of meconium aspiration syndrome. This is similar to our observations in a neonatal model of hypoxia-induced pulmonary hypertension in the newborn piglet. 4 Studies of meconium aspiration in animals clearly require the use of anesthesia to be ethical and to comply with the usual standards. We chose an anesthetic with minimal cardiovascular effects; halothane was given only briefly until an i.v. catheter was inserted, and thereafter a fentanyl anesthetic was used because of minimal hemodynamic effects at these doses. 5, 6 Acepromazine was added at low dose to produce sedation, and pancuronium was used to ensure that the animals were immobile and apneic during the study. The anesthetic was then unchanged throughout the study; the control animals were very stable and demonstrated none of the effects seen in the magnesium-treated animals.
Arterial oxygen saturation decreased significantly after MgSO 4 at doses of 75 and 100 mg/kg. Because there was no evidence of right-to- left shunt and the animals were ventilated at a constant FIO 2 (0.9) throughout the protocol, it is likely that the reduction in SAO 2 after MgSO 4 administration was due to a worsening of ventilation perfusion matching. Magnesium causes relaxation of vascular smooth muscle throughout the pulmonary circulation, including those supplying ventilated and nonventilated alveoli. Increased perfusion of nonventilated areas will lead to a worsening of intrapulmonary shunt and to subsequent hypoxemia.
This aggravation of ventilation perfusion mismatch by vasodilator therapy in a newborn animal model of pulmonary hypertension has not been reported previously and may provide one explanation for the lack of efficacy of systemically administered vasodilators in human infants with persistent pulmonary hypertension of the newborn. 7 Most human infants with persistent pulmonary hypertension of the newborn have some form of parenchymal lung disease and significant ventilation perfusion mismatch. This clinical situation is similar to the model described in this paper and is in contrast to the normal pulmonary function seen in animals with induced alveolar hypoxia. In these clinical situations, the administration of a vasodilator, unless it has selective effects that improve matching of perfusion to ventilation (e.g., inhaled nitric oxide), is likely to cause a worsening of ventilation perfusion matching and a fall in systemic oxygen saturation. Inhaled nitric oxide is a selective pulmonary vasodilator in animal models of persistent pulmonary hypertension of the newborn, 8 ,9 and appears to have beneficial effects in human infants with this condition. 10 Nitric oxide also improves ventilation perfusion matching in a piglet model of meconium aspiration. 11 In this study, the adverse effects of MgSO 4 on SAP were not as pronounced as we noted in our previous study. 4 The smaller reduction in mean SAP may well be because of the model used. The animals in the current study were less hypoxemic, with a mean saturation of 73% compared with 45% in the other study, but they were significantly more acidotic than the animals in the previous study. Magnesium probably reduces vascular tone by blocking the entry of ionic calcium into cells. 12 The acidosis in this study may have prevented some of the adverse effects of MgSO 4 , as acidosis causes an increase in the proportion of calcium that is in an ionized form; therefore, the effects of the MgSO 4 would be expected to be less noticeable. However, we did show a slight decrease in PAP and pulmonary vascular resistance with MgSO 4 therapy, as well as a decrease in systemic pressures.
Studies of adenosine triphosphate (ATP)-MgCl 2 in neonatal animals with pulmonary hypertension have reported a selective pulmonary vasodilation in response to the infusion of a mixture of ATP and magnesium chloride. 13 Similar effects have been noted with ATP alone.
14 Although the MgCl 2 may prevent inactivation of the ATP, it is unlikely to have otherwise contributed to the salutary effects of the ATP. The total dose of magnesium administered by Ali et al. 13 appears to be ϳ0.5 mol/kg per minute, which was infused for ϳ225 minutes. This would give a total dose of 112 mol/kg administered over Ͼ3 hours, which is approximately the same amount of magnesium as our initial bolus dose.
It is not surprising that magnesium, "nature's calcium antagonist," is not a selective pulmonary vasodilator, as both pulmonary and systemic vessels are known to vasodilate in the presence of other calcium channel blockers 15, 16 and MgSO 4 has been used for many years as a systemic hypotensive agent. 17 Other investigators have suggested that clinical trials of MgSO 4 therapy in persistent pulmonary hypertension of the newborn may be appropriate. 1 Our results suggest that great caution should be exercised before deciding to initiate such experiments. 
